Applicability of WNK1 kinase activity modulation toward treatment of podocyte injury was assessed using primary and immortalized podocyte cell lines developed from control and Col4a3<sup>-/-</sup> Alport Syndrome model mice. This evidence concerns the gene COL4A3 and Alport syndrome.